Researchers Recommend Preparticipation Cardiac Screening for College Athletes
According to new study in The American Journal of Medicine
New York, NY, May 25, 2011 – Sudden cardiac death in young athletes who had not previously exhibited symptoms is a relatively rare yet tragic event. This occurs in around 60-80 young athletes annually in the United States. In the June 2011 issue of The American Journal of Medicine, researchers collected electrocardiograms and echocardiograms of 964 athletes at a single university and found that distinct ECG abnormalities were present in 10% and were more common in males as well as black athletes. Two athletes were subsequently excluded from competition.
Investigators from Saint Luke’s Mid America Heart and Vascular Institute, Kansas City, MO, Lawrence Memorial Hospital, Lawrence, KS, and the University of Kansas, Lawrence, prospectively screened male and female varsity athletes enrolled at the University of Kansas, Lawrence. These athletes represented 14 competitive sports with football comprising about 25% of the subjects, rowing 18% and track and field 16%. Close to 9% of all subjects reported a family history of premature death and nearly 15% reported symptoms. Almost 23% of all athletes met the current guidelines for further cardiac testing.
“These findings offer a framework for performing preparticipation screening in competitive collegiate athletes,” commented lead investigator Anthony Magalski, MD, Saint Luke’s Mid America Heart and Vascular Institute, Kansas City. “To our knowledge, this work represents one of the largest single cohorts of collegiate athletes in the US undergoing comprehensive preparticipation screening incorporating both 12-lead electrocardiography and echocardiography in every athlete. The addition of electrocardiography and echocardiography to routine preparticipation history and physical examination provided incremental diagnostic value. Although routinely practiced in Europe, promoted by the International Olympic Committee, and mandated in Italy, preparticipation screening including 12-lead ECG is not commonly performed in competitive collegiate athletes in the US.”
Researchers found that male athletes were nearly 3 times more likely to have distinctly abnormal ECG patterns, while mildly abnormal patterns were similar in males and females. Black athletes were more than twice as likely to have distinctly abnormal ECG patterns, and even after adjusting for sex and body mass index, blacks were still 70 to 80% more likely to show these patterns. However, the racial differences in ECG patterns observed in the current study were not confirmed through echocardiography and this could lead to a higher likelihood of false-positive ECG findings in the black athlete.
The authors point to three novel findings resulting from the study: First, adherence strictly to American Heart Association/American College of Cardiology guidelines for preparticipation screening identified nearly one quarter of athletes who were candidates for noninvasive cardiovascular screening based on history or symptoms. Second, ECG findings revealed clinically important electrical abnormalities in nearly 1% of the cohort, including 7 athletes with previously unrecognized Wolff-Parkinson- White patterns and 1 with long QT syndrome. Third, although black race was independently associated with a greater prevalence of distinctly abnormal ECG patterns, clinically important racial differences in cardiac structure were not apparent.
The article is "Cardiovascular Screening with Electrocardiography and Echocardiography in Collegiate Athletes" by Anthony Magalski, MD, Marcia McCoy, RN, MSN, Michael Zabel, MD, Lawrence M. Magee, MD, Joseph Goeke, MD, Michael L. Main, MD, Linda Bunten, RN, BSN, Kimberly J. Reid, MS, and Brian M. Ramza, MD, PhD. It appears in The American Journal of Medicine, Volume 124, Issue 6 (June 2011) published by Elsevier.
# # #
Notes for Editors
Full text of the article is available to credentialed journalists upon request. Contact Pamela Poppalardo at +1 732-238-3628 firstname.lastname@example.org to obtain copies. To schedule an interview with the authors please contact PJ Longman, Director of Marketing for Cardiovascular Services at Saint Luke’s Health System, at 816-932-2826 or email@example.com.
About The American Journal of Medicine
The American Journal of Medicine ( http://www.amjmed.com), known as the “Green Journal,” is one of the oldest and most prestigious general internal medicine journals published in the United States. It has an Impact Factor of 4.466, which ranks it 14 out of 133 General and Internal Medicine titles according to the Journal Citation Reports® 2009 published by Thomson Reuters.
AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.